Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Pediatr Endocrinol Metab ; 35(3): 325-332, 2022 Mar 28.
Article in English | MEDLINE | ID: mdl-34905667

ABSTRACT

BACKGROUND: Classical homocystinuria (HCU) is an autosomal recessive inborn error of metabolism, which is caused by the cystathionine-ß-synthase (CBS: encoded by CBS) deficiency. Symptoms of untreated classical HCU patients include intellectual disability (ID), ectopia lentis and long limbs, along with elevated plasma methionine, and homocysteine. METHODS: A total of 429 ID patients (age range: 1.6-23 years) were sampled from Northern areas of Punjab, Pakistan. Biochemical and genetic analyses were performed to find classical HCU disease in ID patients. RESULTS: Biochemically, nine patients from seven unrelated families were identified with high levels of plasma methionine and homocysteine. Targeted exonic analysis of CBS confirmed seven causative homozygous mutations; of which three were novel missense mutations (c.451G>T; p.Gly151Trp, c.975G>C; p.Lys325Asn and c.1039 + 1G>T splicing), and four were recurrent variants (c.451 + 1G>A; IVS4 + 1 splicing, c.770C>T; p.Thr257Met, c.808_810del GAG; p.Glu270del and c.752T>C; p.Leu251Pro). Treatment of patients was initiated without further delay with pyridoxine, folic acid, cobalamin, and betaine as well as dietary protein restriction. The immediate impact was noticed in behavioral improvement, decreased irritability, improved black hair color, and socialization. Overall, health outcomes in this disorder depend on the age and symptomatology at the time of treatment initiation. CONCLUSIONS: With personalized treatment and care, such patients can reach their full potential of living as healthy a life as possible. This screening study is one of the pioneering initiatives in Pakistan which would help to minimize the burden of such treatable inborn errors of metabolism in the intellectually disabled patients.


Subject(s)
Cystathionine beta-Synthase , Homocystinuria , Adolescent , Adult , Asian People , Child , Child, Preschool , Cystathionine beta-Synthase/genetics , Cystathionine beta-Synthase/metabolism , Homocystinuria/diagnosis , Homocystinuria/genetics , Homocystinuria/therapy , Humans , Infant , Mutation , Pakistan/epidemiology , Young Adult
2.
Pediatr Neurol ; 102: 62-66, 2020 01.
Article in English | MEDLINE | ID: mdl-31371121

ABSTRACT

BACKGROUND: Hereditary folate malabsorption is a multisystem disease owing to biallelic variants in the gene encoding the proton-coupled folate transporter. Hereditary folate malabsorption is treated with folinic acid, aimed to restore blood and cerebrospinal fluid folate levels. Little is known as to whether oral or intramuscular supplementation of folinic acid is most effective. METHODS: Here we describe a one-year-old boy with hereditary folate malabsorption presenting with the typical features including failure to thrive, aphthous stomatitis, macrocytic anemia along with severe developmental impairment and epilepsy, as well as a magnetic resonance imaging of the brain showing bilateral occipital, cortical calcifications characteristic of hereditary folate malabsorption. We compared the effect of treatment with oral folinic acid versus intramuscular folinic acid supplementation by measuring plasma and cerebrospinal fluid folate levels. RESULTS: Compared with oral administration, intramuscular treatment resulted in higher folate levels in blood and, most importantly, normalization of folate levels in cerebrospinal fluid. Clinically, nearly all systemic and neurological symptoms resolved. CONCLUSION: Normal cerebrospinal fluid folate levels can be achieved in individuals with hereditary folate malabsorption with intramuscular (but not with oral) administration of folinic acid.


Subject(s)
Folic Acid Deficiency/drug therapy , Leucovorin/pharmacology , Malabsorption Syndromes/drug therapy , Vitamin B Complex/pharmacology , Humans , Infant , Injections, Intramuscular , Leucovorin/administration & dosage , Male , Vitamin B Complex/administration & dosage
3.
Front Neurol ; 10: 762, 2019.
Article in English | MEDLINE | ID: mdl-31379716

ABSTRACT

Inborn errors of metabolism (IEMs) are rare group of genetic disorders comprising of more than 1,000 different types. Around 200 of IEMs are potentially treatable through diet, pharmacological and other therapies, if diagnosed earlier in life. IEMs can be diagnosed early through newborn screening (NBS) programs, which are in place in most of the developed countries. However, establishing a NBS in a developing country is a challenging task due to scarcity of disease related data, large population size, poor economy, and burden of other common disorders. Since, not enough data is available for the prevalence of IEMs in Pakistan; therefore, in this study, we set out to find the prevalence of various treatable IEMs in a cohort of intellectually disabled patients suspected for IEMs, which will help us to initiate a NBS program for the most frequent IEMs in Pakistan. Therefore, a total of 429 intellectually disabled (IQ <70) patient samples were collected from Pakistan. A subset of 113 patient samples was selected based on the clinical information for the detailed biochemical screening. Advance analytical techniques like, Amino Acid Analyzer, GC-MS, UHPLC-MS, and MS/MS were used to screen for different treatable IEMs like aminoacidopathies, fatty acid ß-oxidation disorders and mucopolysaccharidoses (MPS) etc. A total of 14 patients were diagnosed with an IEM i.e., 9 with homocystinuria, 2 with MPS, 2 with Guanidinoacetate methyltransferase (GAMT) deficiency and 1 with sitosterolemia. These IEMs are found frequent in the collected patient samples from Pakistan. Thus, present study can help to take an initiative step to start a NBS program in Pakistan, especially for the homocystinuria having highest incidence among aminoacidopathies in the studied patients, and which is amenable to treatment. This endeavor will pave the way for a healthier life of affected patients and will lessen the burden on their families and society.

4.
Blood Adv ; 2(1): 61-68, 2018 01 09.
Article in English | MEDLINE | ID: mdl-29344585

ABSTRACT

Hereditary folate malabsorption (HFM) is an autosomal recessive disorder characterized by impaired intestinal folate absorption and impaired folate transport across the choroid plexus due to loss of function of the proton-coupled folate transporter (PCFT-SLC46A1). We report a novel mutation, causing HFM, affecting a residue located in the 11th transmembrane helix within the external gate. The mutant N411K-PCFT was stable, trafficked to the cell membrane, and had sufficient residual activity to characterize the transport defect and the structural requirements at this site for gate function. The influx Vmax of the N411K mutant was markedly decreased, as was the affinity for most, but not all, folate/antifolate substrates. The greatest loss of activity was for 5-methyltetrahydrofolate. Substitutions with positive charged residues resulted in a loss of activity (arginine > lysine > histidine). Function was retained for the negative charged aspartate, but not the larger glutamate substitutions, whereas the bulky hydrophobic (leucine), or polar (glutamine) substitutions, were tolerated. Homology models of PCFT, in the inward and outward open conformations, based upon the mammalian Glut5 fructose transporter structures, localize Asn411 protruding into the aqueous pathway. This is most prominent when the carrier is in the inward open conformation when the external gate is closed. Mutations at this site likely result in highly specific steric and electrostatic interactions between the Asn411-substituted, and other, residues in the gate region that impede carrier function. The substrate specificity of the N411K mutant may be due to alterations of substrate flows through the external gate, downstream allosteric alterations in the folate-binding pocket, or both.


Subject(s)
Folic Acid Deficiency/genetics , Malabsorption Syndromes/genetics , Mutation, Missense , Proton-Coupled Folate Transporter/genetics , Amino Acid Substitution , Cell Line , Folic Acid Deficiency/etiology , HeLa Cells , Humans , Infant , Malabsorption Syndromes/etiology , Male , Models, Molecular , Mutagenesis, Site-Directed , Protein Transport/genetics , Substrate Specificity , Tetrahydrofolates/metabolism , Transfection
5.
Hum Mol Genet ; 24(12): 3390-8, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-25759467

ABSTRACT

Target of rapamycin complex 1 (TORC1) is an important regulator of neuronal function. However, whereas a modest activation of the TORC1 signaling pathway has been shown to affect synaptic plasticity, learning and memory, the effect of TORC1 hypo-activation is less clear. This knowledge is particularly important since TORC1 inhibitors may hold great promise for treating a variety of disorders, including developmental disorders, aging-related disorders, epilepsy and cancer. Such treatments are likely to be long lasting and could involve treating young children. Hence, it is pivotal that the effects of sustained TORC1 inhibition on brain development and cognitive function are determined. Here, we made use of constitutive and conditional Rheb1 mutant mice to study the effect of prolonged and specific reduction in the TORC1 pathway. We show that Rheb1 mutant mice show up to 75% reduction in TORC1 signaling, but develop normally and show intact synaptic plasticity and hippocampus-dependent learning and memory. We discuss our findings in light of current literature in which the effect of pharmacological inhibition of TORC1 is studied in the context of synaptic plasticity and learning. We conclude that in contrast to TORC1 hyper-activity, cognitive function is not very sensitive to sustained and specific down-regulation of TORC1 activity.


Subject(s)
Monomeric GTP-Binding Proteins/genetics , Mutation , Neuropeptides/genetics , Animals , Brain/metabolism , Brain/physiopathology , Enzyme Activation , Gene Expression , Hippocampus/metabolism , Learning , Long-Term Potentiation/genetics , Maze Learning , Mechanistic Target of Rapamycin Complex 1 , Memory , Mice , Mice, Knockout , Monomeric GTP-Binding Proteins/metabolism , Multiprotein Complexes/metabolism , Neuronal Plasticity/genetics , Neurons/metabolism , Neuropeptides/metabolism , Phosphorylation , Ras Homolog Enriched in Brain Protein , TOR Serine-Threonine Kinases/metabolism
6.
J Neurosci ; 34(34): 11180-7, 2014 Aug 20.
Article in English | MEDLINE | ID: mdl-25143599

ABSTRACT

The α isoform of the calcium/calmodulin-dependent protein kinase II (αCaMKII) has been implicated extensively in molecular and cellular mechanisms underlying spatial and contextual learning in a wide variety of species. Germline deletion of Camk2a leads to severe deficits in spatial and contextual learning in mice. However, the temporal and region-specific requirements for αCaMKII have remained largely unexplored. Here, we generated conditional Camk2a mutants to examine the influence of spatially restricted and temporally controlled expression of αCaMKII. Forebrain-specific deletion of the Camk2a gene resulted in severe deficits in water maze and contextual fear learning, whereas mice with deletion restricted to the cerebellum learned normally. Furthermore, we found that temporally controlled deletion of the Camk2a gene in adult mice is as detrimental as germline deletion for learning and synaptic plasticity. Together, we confirm the requirement for αCaMKII in the forebrain, but not the cerebellum, in spatial and contextual learning. Moreover, we highlight the absolute requirement for intact αCaMKII expression at the time of learning.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Conditioning, Classical/physiology , Fear/physiology , Maze Learning/physiology , Spatial Behavior/physiology , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Conditioning, Classical/drug effects , Estrogen Antagonists/pharmacology , Excitatory Postsynaptic Potentials/genetics , Fear/drug effects , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Hippocampus/cytology , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Integrases/genetics , Integrases/metabolism , Long-Term Potentiation/genetics , Maze Learning/drug effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/physiology , Patch-Clamp Techniques , Spatial Behavior/drug effects , Tamoxifen/pharmacology , Transcription Factors/genetics , Transcription Factors/metabolism
7.
Ned Tijdschr Geneeskd ; 157(43): A6443, 2013.
Article in Dutch | MEDLINE | ID: mdl-24152362

ABSTRACT

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are commonly used biomarkers for liver damage. As well as in liver tissue, AST is also present in cardiac and skeletal muscle and in erythrocytes, making ALT the most specific marker for liver damage. Here, we describe two patients with sustained increases in ALT and AST levels. The first patient is a 79-year-old woman who developed elevated serum transaminases shortly after having a myocardial infarction. The second patient, an obese 40-year-old woman presented with increased ALT and AST levels in the absence of physical symptoms. Notably, her father died of liver cirrhosis without a history of alcohol abuse. Based upon these case reports we discuss the differential diagnostic work-up of elevated serum transaminase levels. Furthermore, we explain monitoring, test performance, reference values and analytical pitfalls of these biomarkers.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Fatty Liver/enzymology , Liver Diseases/enzymology , Adult , Aged , Biomarkers/blood , Diagnosis, Differential , Fatty Liver/diagnosis , Female , Humans , Liver Diseases/diagnosis , Non-alcoholic Fatty Liver Disease , Reference Values
8.
Ann Neurol ; 74(4): 569-79, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23720219

ABSTRACT

OBJECTIVE: Seizure development in tuberous sclerosis complex (TSC) correlates with the presence of specific lesions called cortical tubers. Moreover, heterozygous TSC animal models do not show gross brain pathology and are seizure-free, suggesting that such pathology is a prerequisite for the development of epilepsy. However, cells within TSC lesions show increased activity of the target of rapamycin complex 1 (TORC1) pathway, and recent studies have implicated this pathway in non-TSC-related animal models of epilepsy and neuronal excitability. These findings imply a direct role for TORC1 in epilepsy. Here, we investigate the effect of increased TORC1 signaling induced by acute biallelic deletion of Tsc1 in healthy adult mice. METHODS: Biallelic Tsc1 gene deletion was induced in adult Tsc1 heterozygous and wild-type mice. Seizures were monitored by electroencephalographic and video recordings. Molecular and cellular changes were investigated by Western blot analysis, immunohistochemistry, and electrophysiology. RESULTS: Mice developed epilepsy a few days after biallelic Tsc1 deletion. Acute gene deletion was not accompanied by any obvious histological changes, but resulted in activation of the TORC1 pathway, enhanced neuronal excitability, and a decreased threshold for protein-synthesis-dependent long-term potentiation preceding the onset of seizures. Rapamycin treatment after seizure onset reduced TORC1 activity and fully abolished the seizures. INTERPRETATION: Our data indicate a direct role for TORC1 signaling in epilepsy development, even in the absence of major brain pathology. This suggests that TORC1 is a promising target for treating seizures not only in TSC but also in other forms of epilepsy that result from increased TORC1 activation.


Subject(s)
Epilepsy/genetics , Epilepsy/metabolism , Gene Expression Regulation/genetics , Multiprotein Complexes/metabolism , Sequence Deletion/genetics , TOR Serine-Threonine Kinases/metabolism , Tumor Suppressor Proteins/genetics , Animals , Carrier Proteins/genetics , Carrier Proteins/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Electroencephalography , Epilepsy/pathology , Epilepsy/therapy , Hippocampus/pathology , Immunosuppressive Agents/therapeutic use , Long-Term Potentiation/drug effects , Long-Term Potentiation/genetics , Mechanistic Target of Rapamycin Complex 1 , Mice , Mice, Transgenic , Multiprotein Complexes/genetics , Neurons/drug effects , Neurons/metabolism , Neurons/physiology , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Sirolimus/therapeutic use , TOR Serine-Threonine Kinases/genetics , Tuberous Sclerosis Complex 1 Protein , ras Proteins/metabolism
9.
Cell Cycle ; 10(15): 2412-3, 2011 Aug 01.
Article in English | MEDLINE | ID: mdl-21670600
10.
Mol Cell Biol ; 31(8): 1672-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21321084

ABSTRACT

Ras homolog enriched in brain (Rheb) couples growth factor signaling to activation of the target of rapamycin complex 1 (TORC1). To study its role in mammals, we generated a Rheb knockout mouse. In contrast to mTOR or regulatory-associated protein of mTOR (Raptor) mutants, the inner cell mass of Rheb(-/-) embryos differentiated normally. Nevertheless, Rheb(-/-) embryos died around midgestation, most likely due to impaired development of the cardiovascular system. Rheb(-/-) embryonic fibroblasts showed decreased TORC1 activity, were smaller, and showed impaired proliferation. Rheb heterozygosity extended the life span of tuberous sclerosis complex 1-deficient (Tsc1(-/-)) embryos, indicating that there is a genetic interaction between the Tsc1 and Rheb genes in mouse.


Subject(s)
Gene Expression Regulation, Developmental , Monomeric GTP-Binding Proteins/metabolism , Neuropeptides/metabolism , Animals , Cells, Cultured , Embryo, Mammalian/metabolism , Heterozygote , Mice , Mice, Knockout , Monomeric GTP-Binding Proteins/deficiency , Neuropeptides/deficiency , Ras Homolog Enriched in Brain Protein , Rats , Tuberous Sclerosis Complex 1 Protein , Tumor Suppressor Proteins/deficiency , Tumor Suppressor Proteins/metabolism
11.
Trends Genet ; 24(10): 498-510, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18774199

ABSTRACT

Defects in rat sarcoma viral oncogene homolog (RAS)-extracellular signal regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)-mammalian target of rapamycin (MTOR) signaling pathways have recently been shown to cause several genetic disorders classified as neuro-cardio-facial-cutaneous (NCFC) and Hamartoma syndromes. Although these pathways are well-known players in cell proliferation and cancer, their role in cognitive function is less appreciated. Here, we focus on the cognitive problems associated with mutations in the RAS-ERK and PI3K-MTOR signaling pathways and on the underlying mechanisms revealed by recent animal studies. Cancer drugs have been shown to reverse the cognitive deficits in mouse models of NCFC and Hamartoma syndromes, raising hopes for clinical trials.


Subject(s)
Cognition Disorders/genetics , Extracellular Signal-Regulated MAP Kinases/physiology , Oncogenes/physiology , Protein Kinases/physiology , Animals , Extracellular Signal-Regulated MAP Kinases/genetics , Humans , Models, Biological , Neurotransmitter Agents/metabolism , Protein Biosynthesis/genetics , Protein Kinases/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/physiology , Signal Transduction/genetics , Signal Transduction/physiology , Synaptic Transmission/genetics , TOR Serine-Threonine Kinases
12.
Ann Neurol ; 62(6): 648-55, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18067135

ABSTRACT

OBJECTIVE: Tuberous sclerosis complex (TSC) is characterized by brain lesions, epilepsy, increased incidence of mental retardation and autism. The causal link between lesion load and epilepsy on cognitive disabilities has been debated, and these factors explain only part of the intelligence quotient variability. A Tsc2 rat model of the disease provided evidence that the TSC genes are directly involved in neuronal function. However, these lesion- and epilepsy-free animals did not show learning deficits, leaving open the possibility that the presence of brain lesions or epilepsy is a prerequisite for the cognitive deficits to fully develop. Here, we reinvestigated the relation among cerebral lesions, epilepsy, and cognitive function using Tsc1+/- mice. METHODS: We used immunocytochemistry and high-resolution magnetic resonance imaging to study the presence of neuronal pathology in Tsc1+/- mice. We used the Morris water maze, fear conditioning, social interaction, and nest building test to study the presence of cognitive and social deficits. RESULTS: We observed no spontaneous seizures or cerebral lesions in the brains of Tsc1+/- mice. In addition, giant dysmorphic cells were absent, and spine number and dendritic branching appeared to be normal. Nevertheless, Tsc1+/- mice showed impaired learning in the hippocampus-sensitive versions of the learning tasks and impaired social behavior. INTERPRETATION: Tsc1+/- mice show social and cognitive deficits in the absence of apparent cerebral pathology and spontaneous seizures. These findings support a model in which haploinsufficiency for the TSC genes leads to aberrations in neuronal functioning resulting in impaired learning and social behavior.


Subject(s)
Brain/pathology , Cognition Disorders/genetics , Cognition Disorders/pathology , Mutation , Seizures/genetics , Tumor Suppressor Proteins/genetics , Animals , Behavior, Animal , Cognition Disorders/psychology , Conditioning, Psychological , Dendrites/pathology , Fear , Maze Learning , Mice , Nesting Behavior , Social Behavior , Tuberous Sclerosis Complex 1 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...